BRAIN Biotech AG (BNN.DE)
EUR 3.77
(-3.58%)
EUR 3.77
(-3.58%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 30.12 Million EUR | 9.75% |
| 2022 | 27.44 Million EUR | 27.25% |
| 2021 | 21.57 Million EUR | 1.75% |
| 2020 | 21.2 Million EUR | 0.41% |
| 2019 | 21.11 Million EUR | 57.67% |
| 2018 | 13.39 Million EUR | 5.06% |
| 2017 | 12.74 Million EUR | 12.11% |
| 2016 | 11.36 Million EUR | 12.04% |
| 2015 | 10.14 Million EUR | 26.65% |
| 2014 | 8.01 Million EUR | 37.74% |
| 2013 | 5.81 Million EUR | 68.32% |
| 2012 | 3.45 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 7.06 Million EUR | 524.93% |
| 2024 Q1 | 7.13 Million EUR | -14.08% |
| 2024 Q2 | 1.13 Million EUR | -84.16% |
| 2023 Q1 | 7.12 Million EUR | -5.71% |
| 2023 Q4 | 8.3 Million EUR | 10.73% |
| 2023 FY | 30.12 Million EUR | 9.75% |
| 2023 Q3 | 7.5 Million EUR | 4.37% |
| 2023 Q2 | 7.18 Million EUR | 0.95% |
| 2022 Q2 | 7.46 Million EUR | 28.65% |
| 2022 FY | 27.44 Million EUR | 27.25% |
| 2022 Q4 | 7.55 Million EUR | 13.85% |
| 2022 Q3 | 6.63 Million EUR | -11.12% |
| 2022 Q1 | 5.8 Million EUR | -3.07% |
| 2021 Q1 | 4.18 Million EUR | -0.07% |
| 2021 FY | 21.57 Million EUR | 1.75% |
| 2021 Q2 | 5.55 Million EUR | 32.75% |
| 2021 Q4 | 5.98 Million EUR | 2.48% |
| 2021 Q3 | 5.84 Million EUR | 5.09% |
| 2020 Q4 | 4.18 Million EUR | -25.09% |
| 2020 Q1 | 5.9 Million EUR | 2.39% |
| 2020 Q3 | 5.59 Million EUR | 1.3% |
| 2020 Q2 | 5.52 Million EUR | -6.46% |
| 2020 FY | 21.2 Million EUR | 0.41% |
| 2019 FY | 21.11 Million EUR | 57.67% |
| 2019 Q4 | 5.76 Million EUR | 8.1% |
| 2019 Q3 | 5.33 Million EUR | 23.8% |
| 2019 Q1 | 5.71 Million EUR | 24.57% |
| 2019 Q2 | 4.3 Million EUR | -24.64% |
| 2018 Q2 | 2.68 Million EUR | 6.73% |
| 2018 FY | 13.39 Million EUR | 5.06% |
| 2018 Q4 | 4.58 Million EUR | 27.1% |
| 2018 Q3 | 3.6 Million EUR | 34.61% |
| 2018 Q1 | 2.51 Million EUR | -24.29% |
| 2017 Q3 | 2.75 Million EUR | -21.49% |
| 2017 Q1 | 3.16 Million EUR | 9.14% |
| 2017 Q2 | 3.5 Million EUR | 10.9% |
| 2017 FY | 12.74 Million EUR | 12.11% |
| 2017 Q4 | 3.31 Million EUR | 20.44% |
| 2016 Q4 | 2.89 Million EUR | 6.02% |
| 2016 FY | 11.36 Million EUR | 12.04% |
| 2016 Q3 | 2.73 Million EUR | 2.21% |
| 2016 Q2 | 2.67 Million EUR | -12.59% |
| 2016 Q1 | 3.06 Million EUR | 15.94% |
| 2015 Q1 | 2.95 Million EUR | 0.0% |
| 2015 FY | 10.14 Million EUR | 26.65% |
| 2015 Q2 | 2.18 Million EUR | -25.91% |
| 2015 Q3 | 2.37 Million EUR | 8.4% |
| 2015 Q4 | 2.63 Million EUR | 11.37% |
| 2014 FY | 8.01 Million EUR | 37.74% |
| 2013 FY | 5.81 Million EUR | 68.32% |
| 2012 FY | 3.45 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| BioNTech SE | 3.21 Billion EUR | 99.064% |
| CureVac N.V. | -70.6 Million EUR | 142.661% |
| Biotest Aktiengesellschaft | 271.9 Million EUR | 88.922% |
| Biotest Aktiengesellschaft | 271.9 Million EUR | 88.922% |
| Formycon AG | 23.3 Million EUR | -29.251% |
| Heidelberg Pharma AG | 6.6 Million EUR | -355.974% |
| Medigene AG | 4.39 Million EUR | -585.994% |